CongenItal Naevus Cohort for Longitudinal Evaluation

NANot yet recruitingINTERVENTIONAL
Enrollment

819

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2031

Study Completion Date

June 1, 2031

Conditions
NaeviNeurodevelopmental DisorderCongenital Nevus
Interventions
OTHER

Neurodevelopmental assessment

This assessment will be conducted using the ASQ-3 test. (ASQ-3 stands for Ages and Stages Questionnaires, Third Edition, which is a common screening tool for evaluating developmental progress in young children.)

OTHER

Meeting with the parents

This meeting will evaluate the parents' acceptance of the lesion and their quality of life using the MARKS test (Measure of Acceptance of Skin Marks). The results will provide insights into how the parents perceive the lesion and how it impacts their daily lives.

OTHER

Patient quality of life assessment

Collection of patient quality of life data

Trial Locations (15)

13005

Marseille University Hospital, Marseille

21000

Dijon University Hospital, Dijon

29200

Brest University Hospital, Brest

31300

Toulouse University Hospital, Toulouse

33000

Bordeaux University Hospital, Bordeaux

35000

Rennes University Hospital, Rennes

44300

Nantes University Hospital, Nantes

49100

Angers University Hospital, Angers

54000

Nancy University Hospital, Nancy

59000

Saint Vincent de Paul Hospital, Lille

75015

Paris Necker Hospital, Paris

97400

La Réunion University Hospital, La Réunion

06130

Grasse Hospital, Nice

06200

Nice University Hospital and Lenval Hospital, Nice

Unknown

Tours University Hospital, Tours

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT06828822 - CongenItal Naevus Cohort for Longitudinal Evaluation | Biotech Hunter | Biotech Hunter